Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 30Carcinoma, Hepatocellular 22Small Cell Lung Carcinoma 15Colorectal Neoplasms 14Carcinoma, Non-Small-Cell Lung 14Sarcoma 13Ovarian Neoplasms 12Breast Neoplasms 12Triple Negative Breast Neoplasms 9Nasopharyngeal Carcinoma 9Esophageal Squamous Cell Carcinoma 9Cholangiocarcinoma 9Biliary Tract Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Osteosarcoma 6Lung Neoplasms 6Pancreatic Neoplasms 5Head and Neck Neoplasms 5Esophageal Neoplasms 5Uterine Cervical Neoplasms 4Thyroid Neoplasms 4Neoplasms 4Melanoma 4Solid Tumor 3Recurrence 3Neoplasm Metastasis 3Liver Neoplasms 3Glioma 3Carcinoma, Adenoid Cystic 3Advanced Gastric Cancer 3

Interventions

Oxaliplatin 3Radiotherapy 2Folfox protocol 2Fluorouracil 2Capecitabine 2Bevacizumab 2Artesunate 2camrelizumab 1apatinib 1alectinib 1XELOX 1Trastuzumab 1Ocoxin 1Leucovorin 1Irinotecan 1Drug Therapy 1Chemoradiotherapy 1ABT-165 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Intestinal Neoplasms × apatinib × Clear all
NCT03271255 2019-01-23

Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)

Shenzhen People's Hospital

Phase 2 Unknown
80 enrolled
Gastrointestinal

Digestive System Neoplasms, Gastrointestinal Neoplasms, Intestinal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡